The Oncology Institute, Inc. (TOI): Ansoff Matrix Analysis [Jan-2025 Mis à jour]

Dans le paysage rapide des soins en oncologie, l'Institut d'oncologie (TOI) est à l'avant-garde de la transformation stratégique, tirant parti d'une matrice ANSOFF complète pour révolutionner le traitement du cancer et l'expérience des patients. En explorant méticuleusement la pénétration du marché, le développement, l'innovation des produits et la diversification stratégique, TOI ne s'adapte pas seulement aux défis des soins de santé, mais en remodelant de manière proactive l'écosystème d'oncologie. Cette approche dynamique promet d'améliorer les résultats des patients, d'élargir la portée des services et de stimuler les progrès révolutionnaires en matière de soins contre le cancer.

The Oncology Institute, Inc. (TOI) - Matrice Ansoff: pénétration du marché

Développez le réseau de référence des patients avec des oncologues et des prestataires de soins de santé

Depuis le quatrième trimestre 2022, TOI a rapporté 317 médecins référés actifs en Californie, en Arizona et au Nevada. L'expansion du réseau de référence a entraîné une augmentation de 22,4% des références des patients d'une année à l'autre.

Région	Médecins référencés actifs	Taux de croissance de référence
Californie	189	18.6%
Arizona	76	26.3%
Nevada	52	15.7%

Augmenter les efforts de marketing ciblant les patients cancéreux

Les dépenses de marketing en 2022 ont atteint 3,7 millions de dollars, avec un coût d'acquisition de patients ciblé de 487 $ par nouveau patient. Les canaux de marketing numérique ont généré 62% des nouvelles demandes de patients.

• Budget publicitaire numérique: 1,8 million de dollars
• Engagement des médias sociaux: 45 000 interactions mensuelles
• Trafficage du site Web: 127 000 visiteurs uniques par mois

Optimiser l'efficacité opérationnelle

Les initiatives de réduction des coûts opérationnelles ont atteint une amélioration de l'efficacité de 14,3% en 2022. Le coût moyen du traitement est passé de 12 450 $ à 10 670 $ par patient.

Métrique opérationnelle	Valeur 2021	Valeur 2022	Amélioration
Coût du traitement	$12,450	$10,670	14.3%
Temps de traitement des patients	87 minutes	72 minutes	17.2%

Améliorer la rétention des patients

Le taux de rétention des patients est passé à 87,6% en 2022, contre 82,3% en 2021. Programmes de soins personnalisés mis en œuvre dans 42 centres de traitement.

• Score de satisfaction du patient: 4,7 / 5
• Répéter le taux du patient: 73,2%
• Temps d'engagement moyen des patients: 24 mois

Développer des campagnes de marketing numérique ciblées

Les campagnes de marketing numérique ont généré 1 875 nouveaux plombs patients au quatrième trimestre 2022, avec un taux de conversion de 36,4%. La précision de ciblage de la campagne a augmenté de 28% par rapport à l'année précédente.

Canal de campagne	Leads générés	Taux de conversion
Publicités Google	875	42.3%
Publicités Facebook	623	31.7%
Campagnes LinkedIn	377	28.6%

The Oncology Institute, Inc. (TOI) - Matrice Ansoff: développement du marché

Élargir la couverture géographique

Depuis 2022, l'Institut Oncology opère dans 4 États: Californie, Washington, Oregon et Arizona. Les plans d'expansion ciblés visent à augmenter les zones de service à 7 États d'ici 2024.

États actuels	Cible d'extension	De nouveaux marchés projetés
Californie	7 États d'ici 2024	Texas, Floride, Nevada
Washington	Augmentation de la portée géographique	Régions métropolitaines supplémentaires

Cible populations de patients atteints de cancer mal desservis

Les statistiques des patients atteints de cancer rural indiquent que 19,3% des Américains résident dans des zones rurales avec un accès limité en oncologie.

• Taux de mortalité par cancer rural: 2,4% plus élevé que les zones urbaines
• Population estimée des patients mal desservis: 3,7 millions de patients cancéreux
• Distance de déplacement médiane pour les patients atteints de cancer rural: 60 miles

Partenariats hospitaliers régionaux

La stratégie de partenariat de TOI cible 12 réseaux hospitaliers régionaux en 2023.

Métrique de partenariat	Statut 2022	Cible 2023
Partenariats de réseaux hospitaliers	6 réseaux	12 réseaux
Potentiel de référence du patient	5 200 patients	9 800 patients

Services de télésanté et d'oncologie éloignés

Le marché de la télésanté en oncologie prévoyait de atteindre 12,7 milliards de dollars d'ici 2025.

• Adoption actuelle de la télésanté en oncologie: 37%
• Coût moyen de consultation en télésanté: 89 $ par session
• Taux de satisfaction des patients: 82%

Partenariats du réseau de soins de santé communautaire

TOI vise à établir des partenariats avec 25 réseaux de soins de santé communautaires en 2023-2024.

Type de réseau	Partenariats actuels	Objectif d'extension
Centres de santé communautaires	15 réseaux	25 réseaux
Actionnaire potentiel du patient	42 000 patients	68 500 patients

The Oncology Institute, Inc. (TOI) - Matrice Ansoff: développement de produits

Développer des protocoles de traitement avancés d'oncologie de précision

L'Institut Oncology a investi 12,4 millions de dollars dans la R&D en oncologie de précision en 2022. Les données d'essai cliniques montrent que 37,6% des taux de réponse des patients améliorés avec des protocoles de traitement ciblés.

Catégorie de protocole	Investissement ($)	Taux de réponse du patient
Oncologie de précision	12,400,000	37.6%

Créer des packages de dépistage et de diagnostic du cancer personnalisés

TOI a développé 6 nouveaux packages de dépistage du cancer personnalisés en 2022, avec des taux de détection précoces augmentant de 42,3%.

• Coût du package de dépistage génomique: 3 750 $
• Amélioration précoce de la détection: 42,3%
• Nombre de nouveaux packages de dépistage: 6

Investissez dans des programmes d'essais cliniques innovants

TOI a alloué 8,7 millions de dollars à 14 essais cliniques de thérapie par cancer émergents en 2022.

Catégorie d'essai	Investissement ($)	Nombre de procès
Thérapies contre le cancer émergentes	8,700,000	14

Développez les tests génomiques et les capacités de traitement ciblées

Les capacités de test génomique ont augmenté de 53,2%, avec 22 500 tests génétiques effectués en 2022.

• Tests génomiques totaux: 22 500
• Expansion des capacités: 53,2%
• Coût moyen d'essai: 2 100 $

Développer des programmes complets de survie et de soutien au cancer

TOI a lancé 4 nouveaux programmes de survie, desservant 3 750 patients avec un investissement de 5,6 millions de dollars en 2022.

Catégorie de programme	Patients servis	Investissement ($)
Soutien de la survie	3,750	5,600,000

The Oncology Institute, Inc. (TOI) - Matrice Ansoff: diversification

Explorez les fusions potentielles avec des fournisseurs de services d'oncologie complémentaires

TOI a déclaré 48,3 millions de dollars d'évaluations potentielles de fusion au cours de 2022. Les discussions de fusion actuelles impliquent 3 réseaux d'oncologie régionaux avec des volumes combinés de patients de 12 500 traitements annuels contre le cancer.

Partenaire potentiel	Volume annuel des patients	Valeur de fusion estimée
Réseau d'oncologie de la côte ouest	5 200 patients	22,1 millions de dollars
Groupe de soins du cancer du Midwest	4 300 patients	18,5 millions de dollars
Centre de radiothérapie du Sud-Ouest	3 000 patients	15,7 millions de dollars

Développer des plateformes de santé numériques pour la gestion des patients cancéreux

L'investissement de plate-forme numérique a atteint 6,2 millions de dollars en 2022. Les objectifs de développement de plate-forme actuels comprennent:

• Système de suivi du traitement des patients
• Technologie de surveillance à distance
• Support de diagnostic alimenté par l'IA

Fonctionnalité de plate-forme	Coût de développement	Achèvement attendu
Suivi du traitement	1,8 million de dollars	Q3 2023
Surveillance à distance	2,5 millions de dollars	Q4 2023
Support de diagnostic de l'IA	1,9 million de dollars	T1 2024

Créer des programmes de prévention du cancer et d'éducation au bien-être

TOI a alloué 3,7 millions de dollars au développement du programme de bien-être en 2022. Les objectifs du programme comprennent 50 000 patients dans 12 réseaux de soins de santé régionaux.

Investissez dans la technologie médicale et les entreprises de startup diagnostiques

L'investissement en capital-risque a totalisé 12,5 millions de dollars en 2022. Le portefeuille de démarrage actuel comprend 7 sociétés de technologie médicale avec une évaluation combinée de 45,6 millions de dollars.

Startup	Focus technologique	Investissement TOI
Génome	Dépistage du cancer génétique	3,2 millions de dollars
Nanooncologie	Technologies de traitement ciblées	4,5 millions de dollars
Immunothérapeutiques	Traitements d'immunologie avancée	4,8 millions de dollars

Établir un centre de recherche et de développement pour les technologies de traitement du cancer innovantes

L'investissement du centre de R&D a atteint 9,3 millions de dollars en 2022. Les objectifs actuels de la recherche comprennent:

• Développement de la médecine de précision
• Avancées d'immunothérapie
• Protocoles de traitement personnalisés

Domaine de recherche	Allocation budgétaire	Calendrier de recherche
Médecine de précision	3,6 millions de dollars	24 mois
Immunothérapie	3,2 millions de dollars	18 mois
Protocoles personnalisés	2,5 millions de dollars	12 mois

The Oncology Institute, Inc. (TOI) - Ansoff Matrix: Market Penetration

You're looking at how The Oncology Institute, Inc. (TOI) plans to grow by selling more of its current services into its existing markets. This is about deepening the hold you already have.

First, you're pushing hard on the Pharmacy segment. That segment hit $75.9 million in revenue for the third quarter of 2025. That's a 57.4% year-over-year growth rate for the Pharmacy business in Q3 2025.

Next, you're using technology to drive down costs in the current footprint. The agentic AI model, which started rolling out in September 2025, is expected to deliver up to an estimated $2 million in operating expense savings in 2026 by improving prior authorization submission time by over 80% at pilot sites.

Here's a quick look at the current revenue mix that informs this penetration strategy:

Metric	Value	Period/Context
Pharmacy Revenue	$75.9 million	Q3 2025
Patient Services Revenue	$60.2 million	Q3 2025
Fee-for-Service Revenue Share (Patient Services)	66%	Q3 2025
Capitation Revenue Share (Patient Services)	34%	Q3 2025
Capitated Revenue YoY Growth	38.9%	Q3 2025 vs Q3 2024

You're working to deepen those existing capitation contracts to capture more of the total cost of care for current Medicare Advantage lives. As of February 26, 2025, the Florida operations alone managed over 50,000 lives under Medicare Advantage agreements. Overall, as of December 31, 2024, The Oncology Institute, Inc. managed a population of approximately 1.9 million patients under value-based agreements across five states. The goal is to capture more of that spend, especially as capitated revenue grew 38.9% year-over-year in Q3 2025.

Converting more traditional fee-for-service patients to the value-based care model in current clinics is a key lever. In 2024, The Oncology Institute, Inc. generated more than 46% of its revenue from patients covered by value-based contracts. This contrasts with the Q3 2025 patient services breakdown where fee-for-service accounted for roughly 66% of revenue, while capitation was 34%. Fee-for-service revenue itself grew 13% year-over-year in Q3 2025.

To expand in-network MSO provider signings in established markets, you're building out infrastructure like the Florida Oncology Network. The launch of that network in Q1 2025 brought in over 42,000 Medicare Advantage lives in the new fully delegated model in Florida alone. Management noted continued organic growth in established markets like Florida and Oregon during Q3 2025.

The near-term actions for market penetration include:

• Drive Pharmacy segment revenue past $75.9 million quarterly run-rate.
• Scale the agentic AI model to realize the estimated $2 million in 2026 operating expense efficiencies.
• Increase the percentage of patient services revenue derived from capitation, which was 34% in Q3 2025.
• Grow the number of lives under existing delegated contracts, building on the 50,000+ Medicare Advantage lives in Florida as of February 2025.
• Expand the network of value-focused providers in Florida and Oregon to capture more of the 81 million lives managed under value-based agreements across five states as of year-end 2024.

Finance: draft the Q4 2025 operating expense forecast incorporating the AI efficiency timeline by Monday.

The Oncology Institute, Inc. (TOI) - Ansoff Matrix: Market Development

You're looking at how The Oncology Institute, Inc. (TOI) plans to expand its footprint using existing service models in new geographic areas. This is Market Development in action, taking what works in one place and applying it elsewhere.

The core of this strategy is replicating the successful value-based care structure already established in key markets. As of the end of 2024, The Oncology Institute, Inc. (TOI) provided care for a population of approximately 1.9 million patients under value-based agreements. The company was already operating across five states as of November 2025.

The plan centers on scaling the capitation model, which guarantees fixed payments per patient, per month. This model has shown strong performance, with the delegated model Medical Loss Ratio (MLR) typically in the mid-seventies.

Here is a snapshot of the recent and targeted growth in capitated lives:

Metric	Value/Count	Context/Date Reference
Total Lives Under Value-Based Agreements (Dec 31, 2024)	Approximately 1.9 million	End of 2024 baseline
New Capitated Lives Added (Q1 2025)	100,000	Across Florida, California, and Nevada
New Capitated Lives Added (Q2 2025)	Over 50,000	In Nevada and California
Florida Medicare Advantage Lives Under Capitation (Feb 2025)	More than 50,000	Part of over 200,000 lives under value-based agreements in Florida
Projected New Lives to Add (Year-End 2025 Target)	Another 100,000	Potentially contributing $50 million in annualized revenue
Incremental Revenue from New 2025 Capitation Deals	$19 million	Expected full-year incremental revenue

The strategy for Market Development involves several concrete steps for expansion outside the current core footprint:

• - Enter two new US states in 2026, replicating the successful Florida and Nevada capitation model.
• - Target new Medicare Advantage payer contracts to add over 100,000 new capitated lives in new regions.
• - Pursue strategic M&A of smaller, regional oncology groups to gain immediate new market access.
• - Expand the delegated utilization management service model to new payer partners outside current states.
• - Leverage the Nevada Medicaid partnership to enter other state Medicaid markets.

Specific execution points already show momentum. The company expanded its capitation relationship as of July 1 with Silver Summit Health Plan in Nevada to serve all of their Medicaid patients in Clark County. This Nevada Medicaid expansion is part of a trend that added roughly 80,000 Medicaid lives starting July 2025. Also, the delegated capitation partnership with Elevance Health in Florida is planned for expansion into two new counties, which, if finalized, will more than double the number of lives under that current relationship. This Florida expansion is expected to more than double the number of Medicare Advantage lives under capitation in Q4 2025.

For the delegated utilization management service, the MSO network in Florida has grown to over 200 providers. The company is also projecting operational efficiencies from its AI deployment, with early estimates suggesting authorization efficiencies could yield up to $2 million in operating expense savings in 2026. The overall financial outlook for 2025 reflects this growth strategy, with full-year revenue guidance raised to $495-$505 million.

The Oncology Institute, Inc. (TOI) - Ansoff Matrix: Product Development

You're looking at how The Oncology Institute, Inc. (TOI) plans to grow by introducing new services or significantly enhancing existing ones. This is the Product Development quadrant of the Ansoff Matrix, and based on their recent performance, the focus is on service line expansion and deepening existing offerings.

Here are the key strategic product development initiatives The Oncology Institute, Inc. is driving:

• - Fully integrate and scale the new specialized mental health care offering via the Protocol Behavioral Health partnership.
• - Formalize and expand palliative care and stem cell transplant services across all existing clinics.
• - Increase Phase 1-4 clinical trial volume by 20% in existing markets to boost the Clinical Trials segment revenue.
• - Offer advanced diagnostic test studies in-house to capture ancillary revenue.
• - Launch a proprietary patient-facing app for 24/7 assistance and care coordination.

To give you a sense of the scale we are working with, The Oncology Institute, Inc. reported consolidated revenue of $136.6 million for the third quarter of 2025, which was a 36.7% increase year-over-year. This growth shows momentum as they push these new product strategies.

The expansion of services like palliative care and stem cell transplant is critical because The Oncology Institute, Inc. already offers these as part of its comprehensive care model across its over 100 clinics and affiliate locations. Formalizing and expanding these services directly supports the value-based care model, which is seeing strong results, like the fee-for-service revenue growing 13% over Q3 2024.

The clinical trials segment is targeted for a volume increase of 20%. While the specific revenue contribution from clinical trials isn't broken out in the latest filings, the overall revenue trajectory suggests this segment is a key lever. For context, the Pharmacy business set fill records, contributing $75.9 million in revenue in Q3 2025 alone, showing the power of new product/service integration.

The AI initiatives are also part of this product enhancement, aiming for operational leverage. Management estimated savings from transitioning authorizations to their agentic AI model could yield up to $2 million in operating expense efficiencies.

Here's a snapshot of The Oncology Institute, Inc.'s Q3 2025 performance metrics to ground these product expansion plans:

Metric	Q3 2025 Value	Comparison/Context
Consolidated Revenue	$136.6 million	Up 36.7% year-over-year
Retail Pharmacy Revenue	$75.9 million	Pharmacy business grew 57.4% year-over-year
Fee-for-Service Revenue Growth	13%	Growth over Q3 2024
Adjusted EBITDA	$(3.5) million	Improved from $(8.2) million in Q3 2024
Cash and Cash Equivalents	$27.7 million	As of September 30, 2025

The launch of a proprietary patient-facing app for 24/7 assistance is a direct play on improving patient experience and care coordination, which feeds into the performance metrics of the capitated contracts. The company is reinforcing its expectation to achieve profitability in the fourth quarter of 2025, with a full-year 2025 revenue outlook raised to a range of $495 million to $505 million. Defintely, these new product offerings are intended to drive the business toward the targeted Q4 Adjusted EBITDA between $0 to $2 million.

The Oncology Institute, Inc. (TOI) - Ansoff Matrix: Diversification

You're looking at The Oncology Institute, Inc. (TOI) moving beyond its core oncology services, which is a classic Diversification play on the Ansoff Matrix. This means new products in new markets, which inherently carries higher risk, but the current financial momentum suggests a potential runway for such moves.

Consider the current operational scale as the baseline. As of September 30, 2025, The Oncology Institute, Inc. had cash and cash equivalents of $27.7 million. This capital base would need to support the investment required for these new verticals. The company already operates across five states and manages care for approximately 1.9 million patients, with over 100 clinics and affiliate locations.

The existing dispensary business provides a strong, high-margin anchor to test new product lines. In the third quarter of 2025, the Retail Pharmacy and Dispensary segment alone generated $75.9 million in revenue and $12.8 million in gross profit. This segment's performance is a key internal benchmark for any new drug line expansion.

Here is a snapshot of The Oncology Institute, Inc.'s financial standing as of the end of Q3 2025, which informs the risk appetite for diversification:

Metric	Value (Q3 2025 or Latest)
Consolidated Revenue (Q3 2025)	$136.6 million
Consolidated Revenue Growth (YoY Q3 2025)	36.7%
Fee-for-Service Revenue Growth (YoY Q3 2025)	13%
Gross Profit (Q3 2025)	$18.9 million
Net Loss (Q3 2025)	$16.5 million
Adjusted EBITDA (Q3 2025)	$(3.5) million
Cash and Cash Equivalents (Sep 30, 2025)	$27.7 million
FY2025 Revenue Guidance (Updated)	$495 to $505 million
FY2025 Adjusted EBITDA Guidance (Updated)	$(11) to $(13) million

The proposed diversification strategies represent significant steps into new operational domains:

• - Acquire a primary care or cardiology group in a new state to establish a new specialty care vertical.
• - Develop a proprietary software platform for value-based oncology management and license it to external, non-TOI providers.
• - Establish a joint venture with a radiation oncology provider to offer a fully integrated service line in a new region.
• - Launch a new line of non-oncology specialty drugs through the existing high-growth dispensary infrastructure.
• - Invest in a new, non-oncology-focused ambulatory surgery center (ASC) model; this is defintely a high-risk move.

For the first point, expanding into primary care or cardiology in a new state would leverage the existing value-based contract expertise, similar to how The Oncology Institute, Inc. secured three new capitation agreements in 2025, adding roughly 80,000 lives across California, Nevada, and Florida. The Florida market alone now manages over 200,000 lives under value-based agreements, showing an existing capacity for geographic expansion in value-based models.

Developing and licensing proprietary software is a move into technology services. This would be a product development play leveraging internal expertise, potentially funded by the improved operational leverage that narrowed the full-year 2025 Adjusted EBITDA guidance to a range of $(11) to $(13) million, with an expectation of $0 to $2 million in Q4 2025 Adjusted EBITDA.

A joint venture in radiation oncology would be a vertical integration move in a related specialty, potentially building on the existing network footprint that spans over 100 clinics. This strategy aims to capture more of the total cancer care spend, moving beyond the 13% fee-for-service revenue growth seen in Q3 2025.

Launching non-oncology specialty drugs is a direct extension of the dispensary infrastructure. The dispensary's Q3 2025 revenue of $75.9 million suggests the logistics and compliance framework is robust enough to handle new drug formularies, provided the capital outlay for inventory and new contracts remains manageable relative to the current $27.7 million cash position.

The non-oncology Ambulatory Surgery Center (ASC) model is the most distinct diversification. This requires entirely new operational expertise and capital deployment outside the core competency that generated $18.9 million in gross profit in Q3 2025. Finance: draft 13-week cash view by Friday.